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Abstract
Glial cell line-derived neurotrophic factor (GDNF) is released by glioma cells and pro-
motes tumor growth. We have previously found that GDNF released from the tumor 
cells is a chemoattractant for microglial cells, the immune cells of the central nervous 
system. Here we show that GDNF increases matrix metalloproteinase (MMP) 9 and 
MMP14 expression in cultured microglial cells from mixed sexes of neonatal mice. 
The GDNF-induced microglial MMP9 and MMP14 upregulation is mediated by GDNF 
family receptor alpha 1 receptors and dependent on p38 mitogen-activated protein 
kinase signaling. In organotypic brain slices, GDNF promotes the growth of glioma 
and this effect depends on the presence of microglia. We also previously found that 
MMP9 and MMP14 upregulation can be mediated by Toll-like receptor (TLR) 2 signal-
ing and here we demonstrate that GDNF increases the expression of TLR1 and TLR2. 
In conclusion, GDNF promotes the pro-tumorigenic phenotype of microglia.
This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2021 The Authors. Journal of Neuroscience Research published by Wiley Periodicals, Inc.
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1  | INTRODUC TION
Glioblastoma is a highly malignant brain tumor which comprise ap-
proximately 80% of malignant tumors in the central nervous system 
(Bernstock et al., 2019; Omuro & DeAngelis, 2013). Despite multiple 
strategies to treat glioma including surgery, chemotherapy, and ra-
diotherapy, the medium survival of the patients is only around 12 to 
19 months (Bernstock et al., 2019). It has recently been recognized that 
glioma cells interact with the microenvironment in particular with the 
intrinsic immune cells of the brain, the microglia. These cells together 
with peripheral monocytes infiltrate into the glioma tissue and make up 
30% of the tumor mass (Hambardzumyan et al., 2015). Recent evidence 
indicates that glioma-associated microglia/macrophages (GAMs) partici-
pate in glioma progression via a range of interacting mechanisms (Dzaye 
et al., 2016; Gutmann & Kettenmann, 2019; Hu et al., 2015; Markovic 
et al., 2005). Glial cell-derived neurotrophic factor (GDNF), a member 
of the transforming growth factor-β superfamily, is highly expressed in 
glioma (Wiesenhofer et al., 2000), and promotes the growth, invasion, 
and migration of glioma cells (Ku et al., 2013; Song & Moon, 2006; Xiong 
et al., 2017). Microglia can be attracted to the tumor via GDNF-mediated 
signaling (Ku et al., 2013). GDNF has been shown to promote survival of 
primary microglia (Salimi et al., 2002), to regulate microglial phagocytic 
activity and production of nitric oxide (Chang et al., 2006), as well as to 
inhibit Lipopolysaccharide (LPS)-induced activation of primary rat micro-
glia (Rickert et al., 2014). Hence, GDNF may trigger functional changes 
on microglia after attracting them to the glioma microenvironment.
The matrix metalloproteinases (MMP) 9 and MMP14 participate 
in extracellular matrix digestion, and were found to be upregulated in 
human as well as mouse GAMs. We have previously shown that this 
upregulation can be mediated by toll-like receptor (TLR) signaling 
and activated by an endogenous ligand released from glioma cells, 
versican (Hu et al., 2015). These metalloproteases facilitate tumor 
invasion and progression of glioblastoma multiforme. GDNF is also 
reported to induce the expression of bioactive molecules including 
metalloproteases in glioma cells, thereby promoting progression of 
the tumor (Lu et al., 2010; Qu et al., 2015). In this study we provide 
evidence that GDNF is capable to induce microglial MMP9/14 pro-
duction and thus promotes glioma growth.
2  | METHODS AND MATERIAL S
2.1 | Experimental subjects and ethics approval
C57BL/6J (wild-type, WT) mice were used for microglial primary 
cultures. Neonatal microglia were isolated from male and female 
mice while organotypic brain slices were derived from male mice. 
Transgenic male mice expressing EGFP under the Csf1r promoter 
(CSFR1-EGFP, MacGreen) was used for supplementary organo-
typic brain slices preparation. Studies regarding sex differences, 
which may produce biological variables, were not investigated in 
this study. Mice were all maintained in the animal core facility of 
Max Delbrueck Center. Mice were kept in the animal facility using 
12 hr of light and dark cycle, with food and water ad libitum. For 
organotypic brain slices experiment grouping, slices in each group 
were prepared from four male mice. In total, 34 male WT mice were 
used in organotypic brain slices preparation. Four CSFR1-EGFP mice 
were used in the supplementary organotypic brain slices prepara-
tion. Animals used in this study were handled in accordance with 
German Animal Protection Law as approved by the Regional Office 
for Health and Social Services in Berlin (Landesamt für Gesundheit 
und Soziales, Berlin, Germany, Permit Number (X9005/18)). All ef-
forts were made to minimize pain and suffering.
2.2 | Cell culture
Murine glioma cell line GL261 is isogenic to C57BL/6J mice and was 
obtained from National Cancer Institute, and was cultured in DMEM 
(Gibco-Thermo Fisher Scientific, Waltham, MA, USA) with 10% FCS, 
200 mM glutamine, 100 U/ml penicillin, and 100 ng/ml streptomy-
cin (Invitrogen, Darmstadt, Germany). GL261mCherry cells were gen-
erated as previously described (Hu et al., 2015). Primary microglia 
were prepared from both sexes of neonatal C57BL/6 as previously 
described (Markovic et al., 2009). Briefly, cortical tissue of neonatal 
K E Y W O R D S
GDNF, glioma, microglia, MMP9, MMP14, RRID:AB_10013382, RRID:AB_2107448, 
RRID:AB_2110307, RRID:AB_2111398, RRID:AB_2224402, RRID:AB_2307443, 
RRID:AB_2336933, RRID:AB_2340476, RRID:AB_2619988, RRID:AB_2687825, 
RRID:AB_2721181, RRID:AB_330713, RRID:AB_465440, RRID:AB_490936, 
RRID:AB_657857, RRID:AB_776512, RRID:AB_881233
Significance
This study is a continuation of our research project exam-
ining the interaction between the microglia and glioma. By 
using primary microglia cell and organotypic brain slices, 
we demonstrate that glial cell line-derived neurotrophic 
factor (GDNF) increase matrix metallopeptidase 9 and 
14 expression on microglia via mitogen-activated protein 
kinase signaling cascades, which in turn promote glioma 
growth on the organotypic brain slices. The finding that 
GDNF interferes with glioma promoting activity of micro-
glia could advance the development of new therapeutic 
strategies. Therefore, we believe that our findings are of 
great interest to the neuroscience and medical community.
1050  |     HUANG et Al.
mice was freed of blood vessel and meninges in Hank's balanced salt 
solution (HBSS), and digested in 1% trypsin and 0.05% deoxyribonu-
clease for 5 min at room temperature. Cells were then plated in 75-
cm2 flasks. After 7 days, cells were treated with L929 conditioned 
medium. Microglia were then shaken off and replated. All cells were 
maintained in a 37°C incubator with a 5% CO2 humidified atmosphere.
For GDNF treatment, cells were seeded into 12-well plate to 
be adherent. After 6 hr, 1,000, 2,000, or 4,000 ng/ml recombinant 
GDNF (Peprotech, Rocky Hill, United States) was added into the 
wells and incubated for 6 hr (for qPCR) or 24 hr (for Westernblot or 
ELISA).
2.3 | Organotypic brain slice culture
For organotypic brain slices cultures with tumor inoculation, four 
male C57BL/6J mice for each group were used. For the supple-
mentary figures, male CSF1R-EGFP (Macgreen) mice (Sasmono & 
Williams, 2012) were used to identify microglia. Random p14-old 
C57BL/6J male mice were decapitated and brains were removed 
quickly within 2–3 min and transferred into ice-cold HBSS under 
sterile conditions. After dissecting from brainstem, forebrains were 
glued onto a magnetic block and cut into 250-µm slices on the coro-
nal plane with a vibratome (Leica VT1000S, Wetzlar, Germany). 
Brain sections were then mounted into the 0.4-µm pore size in-
serts with 1ml of culture medium containing DMEM (Gibco-Thermo 
Fisher Scientific, Waltham, Massachusetts, USA) supplemented with 
10% heat-inactivated fetal calf serum (FCS; Invitrogen, Waltham, 
Massachusetts, USA), 0.2 mM glutamine, 100 U/ml penicillin, and 
100 mg/ml streptomycin (all from Gibco). After 24 hr, the slices were 
then changed with cultivation medium which contained 25% heat-
inactivated FCS, 50 mM sodium bicarbonate, 2% glutamine, 25% 
HBSS, 1 mg/ml insulin (all from Gibco), 2.46 mg/ml glucose (Braun, 
Melsungen, Germany), 0.8 mg/ml vitamin C (Sigma-Aldrich, St. Louis, 
MO, USA), 100 U/ml penicillin, 100 mg/ml streptomycin (Gibco), and 
5 mM Tris in DMEM (Gibco).
For GDNF receptor (GFR) and GDNF antibody treatment, 
after tumor inoculation, 1 µg/ml GFR antibody (R and D Systems 
Cat# AF560, RRID:AB_2110307, Minneapolis, United States), 
1 µg/ml GDNF antibody (R and D Systems Cat# AF-212-NA, 
RRID:AB_2111398) or normal goat IgG (R and D Systems) were added 
into the medium of the slices (For details of antibody, see Table 1).
Selective depletion of microglia was done by adding lipo-
some-encapsulated clodronate diluted with culture medium (1:10) to 
the slices. After 48-hr clodronate incubation, the medium was then 
replaced by the cultivation medium and cultured for 72 hr without 
any treatment.
By using micromanipulator to fix the slices in the insert, 5,000 
GL261mCherry in 0.1 µl cell suspension were inoculated into brain 
slices with a 1-µl syringe. The cell suspension was injected slowly 
into the globus pallidus in the cortex. Subsequently, the slices were 
kept in culture for 24 hr, and treatment was added into the cultiva-
tion medium of the slices with medium change every other day.
After 5 days of incubation, the slices were fixed with 4%PFA and 
then mounted on slides. The image was acquired by using confo-
cal microscope (LSM710, Zeiss, Oberkochen, Germany) with z-stack 
scanning, subsequently with 3D rendering and reconstruction by 
IMARIS software (Bitplane, Zürich, Switzerland).
2.4 | Quantitative PCR (qPCR)
Total RNA was extracted from microglia using RNA extraction 
kit (Promega, Madison, WI, USA), and the concentration was de-
termined by NanoDrop 1000 (PeqLab Biotechnologie, Erlangen, 
Germany). Complementary DNA was synthesized by the exten-
sion of oligodeoxythymidine 12–18 primers (0.5 µg/µl) with 200 U/
µl SuperScript II reverse transcriptase (Invitrogen). Gene ampli-
fication was done in triplicate using SYBR Green PCR mix (Roche 
Diagnostics) with the following PCR conditions: 95°C for 10 min, 
95°C for 15 s, and 60°C for 60 s for 40 cycles using the 7500 
Fast real-time qPCR System (Thermo Fisher Scientific). Sequence 
of primers used were synthesized by Biotez GmbH (Berlin, 
Germany): MMP9 (sense 5′-CATTCGCGTGGATAAGGAGT-3′, anti-
sense 5′-ACCTGGTTCACCTCATGGTC-3′), MMP14 (sense 5′-CA 
TCACTGCCCATGAATGAC-3′, anti-sense 5′-GTGCCCTATGCCTA 
CATCCG-3′), TLR1 (sense 5′-TGAGGGTCCTGATAATGTCCTAC-3′, 
anti-sense 5′-AGAGGTCCAAATGCTTGAGGC-3′), TLR2 (sense 
5′-CCCTGTGCCACCATTTCC-3′, anti-sense 5′-CCACGCCCACAT 
CATTCTC-3′), TLR6 (sense 5′-CCAAGAACAAAAGCCCTGAG-3′, an-
ti-sense 5′-TGTTTTGCAACCGATTGTGT-3′), TATA-binding protein 
(TBP; sense 5′-AAGGGAGAATCATGGACCAG-3′, anti-sense 5′-CC 
GTAAGGCATCATTGGACT-3′), interleukin-1 beta (il1β; sense 5′-GC 
AACTGTTCCTGAACTCAACT-3′, anti-sense 5′-ATCTTTTGGGGTC 
CGTCAACT-3′), tumor necrosis factor-alpha (tnfα; sense 5′-CC 
CTCACACTCAGATCATCTTCT-3′, anti-sense 5′-GCTACGACGTGG 
GCTACAG-3′), Arginase 1 (arg1; sense 5′-CTCCAAGCCAAAGTC 
CTTAGAG-3′, anti-sense 5′-AGGAGCTGTCATTAGGGACATC-3′), 
and interleukin-10 (il10; sense 5′-GCTCTTACTGACTGGCATGAG-3′, 
anti-sense 5′-CGCAGCTCTAGGAGCATGTG-3′). Expression changes 
in specific genes were analyzed by comparative 2(−ΔΔCt) methods 
relative to TBP gene expression levels.
2.5 | Western blot
Whole-cell protein was extracted from microglia treated with 
GDNF or other treatment by radioimmunoprecipitation assay 
lysis buffer (Sigma-Aldrich, St. Louis, USA) containing EDTA-free 
protease inhibitor cocktail tablets (Roche Diagnostics, Basel, 
Switzerland). Protein concentration was determined by a bicin-
choninic acid protein assay kit (Thermo Fisher Scientific, Waltham, 
USA). After adjusting to 20 µg of total protein, protein lysate was 
then electrophoresed in the 10% sodium dodecyl sulfate–po-
lyacrylamide electrophoresis gel. After wet-transferring the pro-
teins onto polyvinylidene difluoride membrane (Sigma-Aldrich), 
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the membrane was then incubated in the 5% bovine serum albu-
min (BSA, Carl-Roth, Karlsruhe, Germany) in phosphate-buffered 
saline (PBS)–Tween 20, (pH 7.4), followed by primary antibodies 
(MMP9: Abcam, Cambridge, United Kingdom, Cat# ab38898, 
RRID:AB_776512, 1:500; MMP14: Abcam Cat# ab53712, 
RRID:AB_881233, 1; 1,000; GAPDH: Abcam Cat# ab8245, 
RRID:AB_2107448, 1:2,000) incubation overnight at 4°C. The 
membranes were rinsed with PBS–Tween20 to remove the pri-
mary antibody and then incubated with secondary antibodies 
(Goat anti-Rabbit IgG Secondary antibodies: LI-COR Biosciences, 
Cat# 925-68071, RRID:AB_2721181, 1:5,000; Goat anti-Mouse 
IgG Secondary antibodies: LI-COR Biosciences, Cat# 925-32210, 
RRID:AB_2687825, 1:5,000) (For details of antibody, see Table 1). 
After washing again with PBS–Tween20, the label was then de-
tected by Odyssey imaging system (LI-COR, Lincoln, USA). The 
values of the samples were quantified by using ImageJ software 
(National Institutes of Health). The difference of expression level 
was analyzed by normalizing target protein signals to house-keep-
ing protein in each sample.
2.6 | Enzyme-linked immunosorbent assay (ELISA)
Supernatant from microglial cultures or organotypic brain slices was 
collected and samples were centrifuged for 20 min at 1,000× g. The 
whole assay was performed according to the manufacturer's proto-
col (CUSABIO, TX, USA). Briefly, after reagent preparation, standard 
was added into the tubes at different concentrations to achieve a 
gradient. Next, standard and samples were added into the well of 
the ELISA plate and incubated for 2 hr at 37°C followed by superna-
tant removal. Biotin-antibody was added to each well and incubated 
for 1 hr at 37°C. Subsequently, HRP-avidin was added to each well 
after washing. The wells were then repeatedly washed and TMB 
substrate was added and incubated for 15 min at 37°C. Finally, stop 
solution was applied to each well and the optical density of the plate 
was determined by a microplate reader at 450 nm. The quantifica-
tion was performed by comparing a standard curve to the read out 
of samples.
2.7 | Flow cytometry
Microglia were pretreated with SB202190 for 3 hr and subsequently 
stimulated with 4,000 ng/ml GDNF for 24 hr. The cells were then 
detached and incubated with TLR1 (Thermo Fisher Scientific, Cat# 
12-9011-80, RRID:AB_657857) and TLR2 (Thermo Fisher Scientific, 
Cat# 11-9021-82, RRID:AB_465440) FACS antibody (Thermo Fisher 
Scientific, Massachusetts, United States) (For details of antibody, 
see Table 1). Data were analyzed using FlowJo software (Treestar, 
Ashland, OR, USA). Flow cytometry data were quantified by median 
fluorescence intensity and presented in histograms.
2.8 | CCK-8 viability assay
Supernatant from the GL261 cells or organotypic brain slices were 
collected into 96-well plate. CCK-8 reagent (Toyobo, Osaka, Japan) 
was added (10 μl per well) into the wells containing supernatant in 
96-well plate and incubated for 2 hr. Plates were measured with a 
multireader at 450 nm absorbance. Results were normalized to the 
absorbance of the control group.
2.9 | Immunofluorescence staining
Organotypic brain slices were fixed with 4% PFA and subsequently 
washed with 0.1 M phosphate buffer (PB). After blocking with 2% 
Triton-X (Sigma-Aldrich), 2% BSA (Carl-Roth), 10% normal donkey 
serum (Sigma-Aldrich) in 0.1M PB was incubated for 3 hr at room 
temperature. Slices were then incubated with primary antibodies so-
lution (Iba-1: Abcam Cat#ab5076, RRID:AB_2224402, 1:250; GFAP: 
Dako, Jena, Germany, Cat#Z0334, RRID:AB_10013382, 1:400; 
NeuN: Synaptic Systems, Goettingen, Germany, Cat# 266 004, 
RRID:AB_2619988, 1:500) at 4°C overnight. Followed by washing, 
slices were next incubated with secondary antibodies (Alexa Fluor 
488-AffiniPure Donkey Anti-Goat IgG (H+L): Dianova, Hamburg, 
Germany, Cat# 705-545-147, RRID:AB_2336933, 1:250; Alexa 
Fluor 647-AffiniPure Donkey Anti-Guinea Pig IgG (H+L): Dianova 
Cat#706-605-148, RRID:AB_2340476, 1:250; Cy3-AffiniPure 
Donkey Anti-Rabbit IgG (H+L): Dianova Cat# 711-165-152, 
RRID:AB_2307443, 1:250) and DAPI (Sigma-Aldrich) at room tem-
perature for 2 hr, followed by washing (For details of antibody, see 
Table 1). The slices were mounted in Aquapolymount (Polysciences, 
Inc., Warrington, United States) and images were taken by LSM 700 
confocal microscope (Zeiss, Oberkochen, Germany).
2.10 | Statistical analysis
All data are represented as mean ± SD. Data sets were analyzed 
statistically by Graphpad Prism 7.0 software (Graphpad, San Diego, 
USA). Differences between two samples were measured by the un-
paired two tailed Student's t-test while statistical differences among 
multiple samples were assessed by one-way ANOVA with Tukey's 
post hoc comparison test. For organotypic brain slice with tumor 
inoculation, all the values of tumor volumes/area from different 
mice were pooled together for one-way ANOVA or t-test analysis. 
As for antibodies treatment, comparison was made among isotype 
control and antibody treatment group using one-way ANOVA with 
Tukey's post hoc comparison test. Pearson's product-moment cor-
relation was used to identify the co-relationship between GDNF and 
MMPs via published processing website (http://gliov is.bioin fo.cnio.
es/). Data that could not be measured because of technical limita-
tions were not included in the ANOVA statistical tests (data of three 
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TA B L E  1   List of used antibodies
Antibody Supplier information RRID Immunogen Dilution










GAPDH Abcam RRID:AB_2107448 Rabbit muscle GAPDH 1:2,000
Mouse monoclonal
Cat# ab8245
p38 MAPK Cell Signaling Technology RRID:AB_330713 p38 MAP Kinase Antibody detects 





Phospho-MAPKAPK-2 (p-Mk2) Cell Signaling Technology RRID:AB_490936 Phospho-MAPKAPK-2 (Thr334) (27B7) 
Rabbit mAb detects endogenous levels 
of MAPKAPK-2 protein only when 




TLR1 Thermo Fisher Scientific RRID:AB_657857 Mouse Toll-like receptor 1 (TLR1, CD281) 1:100
Rat monoclonal
Cat# 12-9011-80
TLR2 Thermo Fisher Scientific RRID:AB_465440 Mouse Toll-like receptor 2 (TLR1, CD282) 1:100
Rat monoclonal
Cat# 11-9021-82
GFRα1 R and D Systems RRID:AB_2110307 Mouse myeloma cell line NS0-derived 






GDNF R and D Systems RRID:AB_2111398 E. coli-derived and Mouse myeloma cell 






GFAP Dako RRID:AB_10013382 GFAP isolated from cow spinal cord 1:400
Rabbit polyclonal
Cat# Z0334
NeuN Synaptic Systems RRID:AB_2619988 Recombinant protein corresponding to AA 




Iba-1 Abcam RRID:AB_2224402 Synthetic peptide corresponding to 




IRDye® 680RD Goat anti-Rabbit 
IgG Secondary antibodies
LI-COR Biosciences RRID:AB_2721181 Rabbit IgG 1:5,000
Goat
Cat# 925-68071
IRDye® 800CW Goat anti-Mouse 
IgG Secondary antibodies
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samples in control group of Figure 5d; data of two samples in isotype 
group of Figure 6e). Statistics, actual p values, when significant, and 
number of samples were reported in the text. Data were analyzed 
by a person who was blind to experimental conditions. Statistical 
significance in the figures is indicated as: *p < 0.05; **p < 0.01; 
***p < 0.001; ****p < 0.0001, ns = p > 0.05.
3  | RESULTS
3.1 | GDNF increases MMP9 and MMP14 
expression in cultured microglia
To examine the effect of GDNF on the expression of MMP9 and 
MMP14, cultured microglial cells from postnatal brain were treated 
with two different concentrations of GDNF (1,000, 4,000 ng/ml) for 
6 hr. Expression levels of MMP9 and MMP14 were determined by 
RT-qPCR. 1,000 ng/ml GDNF increased MMP9 and MMP14 by 2.05 
(unpaired t-test, t(12) = 8.81, p < 0.0001, n = 7)- and 1.42 (unpaired 
t-test, t(12) = 3.432, p = 0.005, n = 7)-fold while 4,000 ng/ml in-
creased MMP9 and MMP14 by 3.37 (unpaired t-test, t(12) = 5.673, 
p = 0.001, n = 7)- and 2.75-fold (unpaired t-test, t(12) = 3.46, , 
p = 0.0047, n = 7), respectively (Figure 1a,b).
GDNF is unstable in solution, loses its biological activity within 
2 weeks and can be stabilized by dissolving in 0.1% BSA containing 
PBS (according to the guidelines by Peprotech, Rocky Hill, CT, USA). 
This improves GDNF stability and it remains active for several months. 
Since BSA has been shown to promote IL-1β and TNF-α secretion in 
the N9 microglial cell line (Zhao et al., 2009), we first tested BSA alone. 
MMP9 and MMP14 mRNA expression levels increased significantly 
between the plain PBS and the 0.1% BSA in PBS (PBSB), showing that 
BSA indeed has an effect by its own (Figure S1a). While 1,000 ng/
ml of GDNF increased MMP9 and MMP14 1.69 (unpaired t-test, 
t(4) = 7.575, p = 0.0016, n = 3) and 1.85 (unpaired t-test, t(4) = 4.923, 
p = 0.0079, n = 3) times, respectively, as compared to the PBS control, 
4,000 ng/ml led to a 4.61 (unpaired t-test, t(4) = 3.556, p = 0.0237, 
n = 3) and 5.64 times (unpaired t-test, t(4) = 7.08, p = 0.0021, n = 3) 
increase for MMP9 and MMP14, respectively (Figure S1b).
Additionally, we determined protein expression levels of MMP9 
and MMP14 by western blot 24 hr after treatment of microglia with 
4,000 ng/ml GDNF. Both MMP9 and MMP14 protein expression in-
creased significantly compared to PBSB (PBS with 0.1% BSA as vehicle) 
control (unpaired t-test, MMP9: 0.20 ± 0.04 vs. 0.52 ± 0.08, t(6) = 3.916, 
p = 0.0078; MMP14: 0.7398 ± 0.04732 vs. 1.134 ± 0.08225, 
t(6) = 7.563, p = 0.0003, n = 4, Figure 1c,d). To determine that MMPs are 
released from microglia after GDNF stimulation, primary microglia cells 
were treated with GDNF for 24 hr and MMP14 was determined in the 
supernatant of the culture via ELISA. Indeed, higher level of MMP14 was 
determined in the supernatant in the GDNF-treated culture compared 
to control (unpaired t-test, t(6) = 5.439, p = 0.0016, n = 4, Figure 1e). 
To study the impact of GDNF on markers of microglial activation, we 
studied the expression of cytokines IL-1β, TNF-α and IL10 and Arg1 by 
qPCR after GDNF treatment. We did not observe significant changes in 
these marker genes (Figure 1f), indicating GDNF did not alter microglia 
inflammatory phenotype.
3.2 | GDNF-mediated MMP9/MMP14 expression is 
dependent on p38 MAPK signaling
GDNF can activate the p38 mitogen-activated protein kinase 
(MAPK) signaling pathway to promote the migration of glioma cells 
(Song & Moon, 2006). In an in vitro experiment, glioma cell-condi-
tioned medium (GCM) has also been shown to increase MMP9 and 
MMP14 expression in microglia via the p38 MAPK signaling pathway 
(Hambardzumyan et al., 2015; Hu et al., 2015; Markovic et al., 2005). 
To test whether the GDNF-induced MMP9/MMP14 expression in 
microglia is dependent on p38 MAPK signaling, we made use of 
SB202190, a highly selective, potent, and cell permeable inhibitor of 
p38 MAPK. We first tested whether GDNF affects the expression of 
p38 MAPK and MAPK-activated protein kinase 2 (MK2), a substrate 
of p38 MAPK. We pretreated primary microglia with SB202190 for 
3h, stimulated with 4,000 ng/ml GDNF for 24 hr and examined pro-
tein expression levels of p38 and phosphorylated MK2. As expected, 
pretreatment with SB202190 did not affect p38 expression levels 
(Figure 2a), but attenuated the GDNF-induced phosphorylation of 
MK2 (Figure 2b).
To test whether GDNF triggers MMP9 and MMP14 expres-
sion via p38, primary microglia were pretreated for 3 hr with 10 µM 
SB202190, subsequently GDNF was added for 6h, RNA was extracted 
Antibody Supplier information RRID Immunogen Dilution
Alexa Fluor 488-AffiniPure 
Donkey Anti-Goat IgG (H+L)
Dianova RRID:AB_2336933 Reacts with whole molecule goat 1:250
Donkey polyclonal
Cat# 705-545-147 IgG
Alexa Fluor 647-AffiniPure 
Donkey Anti-Guinea Pig IgG 
(H+L)
Dianova RRID:AB_2340476 Reacts with whole molecule 1:250
Donkey polyclonal
Cat#706-605-148 guinea pig IgG
Cy3-AffiniPure Donkey Anti-
Rabbit IgG (H+L)
Dianova RRID:AB_2307443 Reacts with whole molecule rabbit 1:250
Donkey polyclonal
Cat# 711-165-152 IgG
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and MMP9 and MMP14 expression examined by RT-qPCR. SB202190 
significantly inhibited GDNF-induced MMP9 (one-way ANOVA with 
Tukey's post hoc test, F(3, 20) = 9.762, p = 0.0004, n = 6; GDNF 
vs. SB202190 + GDNF, p = 0.0035, Figure 3a) and MMP14 expres-
sion (one-way ANOVA with Tukey's post hoc test, F(3, 12) = 15.56, 
p = 0.0002, n = 6; GDNF vs. SB202190 + GDNF, p = 0.0004, 
Figure 3b). The inhibition of the GDNF-induced MMP14 upregula-
tion by SB202190 could also be confirmed by western blot analysis. 
MMP14 expression after GDNF stimulation was reduced by SB202190 
(Figure 3c) that is in line with previously shown mRNA expression data. 
Together, these results provide evidence that p38 MAPK signaling 
plays a role in GDNF-mediated microglial MMP9/14 expression.
F I G U R E  1   Glial cell line-derived neurotrophic factor (GDNF) increases matrix metallopeptidase 9 (MMP9) and MMP14 expression in 
primary-cultured microglia in a dose-dependent fashion. (a,b) MMP9 and MMP14 mRNA levels were measured by qPCR after stimulation 
of cultured microglial cells with 1,000 and 4,000 ng/ml GDNF for 6 hr while BSA PBS served as a control (n = 7 each group). (c,d) MMP9 
and MMP14 protein levels were determined by western blot after stimulation with 4,000 ng/ml for 24 hr compared to PBSB. GAPDH level 
served as reference. The blot is shown on the left, the quantification on the right (n = 4 each group). (e) MMP14 level in the supernatant of 
microglial cultures treated with 4,000 ng/ml GDNF for 24 hr was determined by ELISA assay. (f) Microglial phenotype genes on cultured 
microglia treated with 4,000 ng/ml GDNF for 6 hr determined by qPCR. Arg1, Arginase 1; Il1β, interleukin-1 beta; il10 = interleukin-10; tnfα, 
tumor necrosis factor alpha; PBSB, 0.1% BSA in PBS. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001
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3.3 | GDNF increases expression of TLR1 and TLR2, 
but not TLR6 in a p38-dependent fashion
We have previously shown that in a glioma context, MMP9/MMP14 
expression on microglia was induced by TLR2 activation. TLR2 
forms heterodimers with TLR1 or TLR6 to transmit signaling (Li 
et al., 2013). We therefore addressed the question whether GDNF 
might regulate TLR expression. Primary microglia were treated with 
GDNF (1,000 and 4,000 ng/ml, dissolved in 0.1% BSA contain-
ing PBS) for 6 hr and subsequently we determined the expression 
level of TLR1/2/6 by qPCR. GDNF increased the expression of TLR 
2 at 1,000 and 4,000 ng/ml by 1.65 (unpaired t-test, t(12) = 4.96, 
p = 0.0003, n = 7)- and 2.41 (unpaired t-test, t(12) = 4.298, 
p = 0.001, n = 7)-fold, respectively (Figure 4a). TLR1 was increased 
at 1,000 ng/ml by 1.16-fold (unpaired t-test, t(6) = 4.1, p = 0.0064, 
n = 4), and at 4,000 ng/ml by 1.81-fold (unpaired t-test, t(6) = 4.245, 
p = 0.0054, n = 4) (Figure 4a). In contrast, we did not observe a sig-
nificant increase in TLR6 expression at 1,000 or 4,000 ng/ml GDNF 
(Figure 4a). Moreover, TLR1 and TLR2 expression increased in a 
similar fashion when GDNF was dissolved without BSA compared to 
plain PBS when used within 14 days after dissolving GDNF (Figure 
S1c,d).
We then tested whether p38 MAPK signaling is involved in GDNF-
induced expression of TLR1 and 2 in microglia. We pretreated microglia 
with the p38 inhibitor SB20219 for 3 hr, stimulated with 4,000 ng/ml 
GDNF for 6 hr and determined TLR1 and 2 expression levels by 
qPCR. The inhibition of p38 MAPK signaling abrogated the GDNF-
induced upregulation of TLR1 (F(3, 12) = 148.1, p < 0.0001, n = 4 
per group) and TLR2 (one-way ANOVA with Tukey's post hoc test, 
F(3, 16) = 14.7, p < 0.0001, n = 4 per group), suggesting that p38 
MAPK signaling plays a role in GDNF-induced TLR1/2 expression in 
microglia (Figure 4b). Finally, protein level of microglial TLR2 was de-
termined by flow cytometry after treated with GDNF with or without 
P38 inhibitor pretreatment. Similar to qPCR data, TLR2 expression 
increased after GDNF stimulation while p38 inhibition attenuated 
the GDNF attributed TLR2 upregulation (one-way ANOVA with 
Tukey's post hoc test, F(3, 20) = 118.3, p < 0.0001, n = 6 per group, 
Figure 4c).
F I G U R E  2   Glial cell line-derived neurotrophic factor (GDNF) did not affect p38 mitogen-activated protein kinase (MAPK) expression, 
but increased phosphorylation levels of MK2 in primary microglia. Primary microglia were pretreated for 3 hr with 10 µM SB202190, then 
stimulated with 4,000 ng/ml GDNF for 6/24 hr. Subsequently protein level of p38 MAPK (a) and p-MK2 (b) was extracted and analyzed by 
western blot. The blot is shown on the left, the quantification on the right. GAPDH level served as reference. Data represent at least three 
independent experiments (n = 4 each group)
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3.4 | The effect of GDNF on glioma growth 
in organotypic brain slices
Since we found that GDNF can induce MMP9 and MMP14 upregu-
lation in microglia and since MMP9 and MMP14 released from mi-
croglia were found to promote glioma cell growth and expansion, 
we tested whether GDNF has an impact on glioma cell growth. We 
generated organotypic brain slice culture organotypic brain slice 
(OBS) and inoculated mCherry-labeled GL261 glioma cells to moni-
tor glioma growth as previously described (Figure 5a) (Markovic 
et al., 2005). Slices were maintained for 5 days and GDNF was 
added to the medium of the organotypic brain slices and compared 
to untreated slices as control. Subsequently slices were fixed and 
the tumor volume was measured by z-stack scanning with a confo-
cal microscope followed by 3D reconstruction with Imaris software 
(Figure 5b). At a concentration of 1,000 ng/ml GDNF, we did not 
observe a significant impact on tumor volume while 2,000 and 
4,000 ng/ml of GDNF significantly increased the tumor volume (for 
2,000 ng/ml: unpaired t-test, t(24) = 2.916, p = 0.0076, n = 12 per 
group; for 4,000 ng/ml: unpaired t-test, t(26) = 3.457, p = 0.0019) 
(Figure 5c). To test whether the impact of GDNF on glioma growth 
is mediated by microglia, we depleted microglia from OBS by treat-
ment with clodronate liposome for 48 hr prior to GDNF stimulation. 
The microglia depletion on organotypic brain slices was confirmed 
by using CSF1R-EGFP mice (Sasmono & Williams, 2012). Significant 
and efficient microglia depletion was observed after clodronate li-
posome treatment (Figure S2a) while no significant changes were 
found with respect to morphology of astrocytes or neurons (Figure 
S2b). In microglia-depleted slices, tumor growth was lower as pre-
viously described and there was no significant difference between 
F I G U R E  3   Glial cell line-derived neurotrophic factor (GDNF)-mediated matrix metallopeptidase 9 (MMP9) and MMP14 expression 
is dependent on p38 mitogen-activated protein kinase (MAPK) signaling. (a) Cultured microglia were pretreated for 3 hr with 10 µM 
SB202190 compared to an untreated control, then stimulated with 4,000 ng/ml GDNF for 6 hr and compared to the unstimulated control. 
Subsequently the level of MMP9 mRNA was detected by qPCR (n = 6 each group). (b) Similar experiment as shown in A for MMP14. (c) 
Similar experimental arrangement as described in A for western blot of MMP14 after 24 hr incubation. GAPDH level served as reference. 
The blot is shown on the left, and the quantification on the right (n = 4 each group)
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GDNF-treated and untreated slices (one-way ANOVA with Tukey's 
post hoc test, F(3, 68) = 15.56, p < 0.0001; specifically, clodronate 
vs. clodronate + GDNF, p > 0.9999, n = 18 per group, Figure 5d).
In order to confirm that also endogenous GDNF induced tumor 
growth in OBS, we used a GDNF neutralizing antibody to block 
the GDNF in the organotypic brain slices after GL261mCherry 
inoculation. Indeed, tumor volume was significantly lower by 
0.81-fold when the slices were treated with GDNF neutralizing 
antibody (1 μg/ml) (one-way ANOVA with Tukey's post hoc test, 
F(2, 51) = 3.782, p = 0.0294; specifically, Isotype vs. anti-GDNF, 
13.0 ± 0.8 vs. 10.5 ± 0.5 × 106 μm3, p = 0.0399, n = 18 per group, 
Figure 5e). Besides, OBS were treated with GDNF and protein 
level of MMP14 was analyzed by western blot. We found that 
GDNF significantly upregulated MMP14 protein expression in 
F I G U R E  4   Glial cell line-derived neurotrophic factor (GDNF) induces expression of toll-like receptor (TLR)1 and TLR2 in primary 
microglia in a p38-dependent fashion. (a) Cultured microglia were treated with two different concentrations of GDNF (1,000 and 4,000 ng/
ml) for 6 hr and TLR1/2/6 expression was determined by RT-qPCR analysis. Data represent four to seven independent experiments and 
are normalized to TATA-binding protein (TBP, n = 4 each group). (b) Microglia were pretreated with 10 µM SB202190 for 3 hr similar as 
described in the legend to Figure 2, subsequently stimulated with 4,000 ng/ml GDNF for 6 hr and TLR1 and TLR2 expression was examined 
by RT-qPCR (n = 5 each group). (c) Protein level of TLR2 after 24 hr treatment with 4,000 ng/ml GDNF was determined by flow cytometry, 
with representative histogram on the left. We also applied 10 µM SB202190 for 3 hr similar as described in the legend to Figure 2 and 
quantification of the data is shown on the right (n = 6 each group) [Color figure can be viewed at wileyonlinelibrary.com]
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the ex vivo slices (Figure 5f), indicating that the GDNF-induced 
ex vivo tumor growth might be due to higher level of MMP14. In 
addition, to test whether the MMPs upregulation occurred in a 
microglia-dependent manner in the organotypic brain slices, we 
compared control slices with microglia-depleted slices. We ob-
served that microglia depletion by clodronate attenuated GDNF-
induced MMP14 upregulation (Figure 5h). Furthermore, this 
finding was validated by determining MMP14 in the supernatant 
from organotypic brain slice via ELISA (one-way ANOVA with 
Tukey's post hoc test, F(2, 9) = 65.39, p < 0.0001, specifically, 
GDNF vs. clodronate + GDNF, p < 0.0001, n = 4 per group, 
Figure 5i).
Since GDNF has been postulated to directly promote glioma cell 
growth (Wiesenhofer et al., 2000; Xiong et al., 2017), we measured 
GL261 proliferation activity by CCK-8 cell counting kit. GDNF did 
not significantly promote GL261 cell proliferation in the concentra-
tion range from 1,000 to 4,000 ng/ml (Figure 5g).
To substantiate our findings in human glioma, we performed the 
meta-analysis to check the expression relationship between GDNF 
and MMP9 or MMP14 on TCGA database with GLIOVIS software 
     |  1059HUANG et Al.
(http://gliov is.bioin fo.cnio.es/) (Bowman et al., 2017). A significant 
correlation was found between GDNF and MMP14 (Pearson's prod-
uct-moment correlation, r = 0.21, p < 0.001, n = 538 in total, Figure 
S1e). However, no significant correlation was found between GDNF 
and MMP9 (Pearson's product-moment correlation, r = −0.01, 
p = 0.85, n = 538 in total, Figure S1f).
3.5 | The GDNF-induced microglial MMP9 and 
MMP14 upregulation and glioma expansion is 
mediated by GFRα1 receptors
GDNF signaling is mainly mediated by a two-component receptor 
consisting of a GDNF binding domain, the GFRα, a GPI-anchored 
receptor, and a signal transducing domain RET, a receptor tyrosine 
kinase. Among the four family members of the GFRα1-4, GDNF 
has a strong binding activity to GFRα1, which mediates the GDNF-
induced autophosphorylation and activation of the RET receptor 
(Ibáñez & Andressoo, 2017). We therefore used a neutralizing anti-
body to GFRα1 to block GFRα1 signaling. Microglial cells were pre-
treated with the antibody against GFRα1 for 3 hr and subsequently 
GDNF was applied for 6 hr and the level of MMP9 and MMP14 was 
measured by qPCR. We found that after GFRα1 blockade, GDNF 
did not trigger an increase in the mRNA level of MMP9 (one-way 
ANOVA with Tukey's post hoc test, F(3, 12) = 11.92, p = 0.0007; 
specifically, GDNF+Isotype vs. GDNF+aGFR1, p = 0.0085, n = 4 per 
group, Figure 6a) and MMP14 (one-way ANOVA with Tukey's post 
hoc test, F(3, 12) = 29.78, p < 0.0001; specifically, GDNF+Isotype 
vs. GDNF+aGFR1, p = 0.0006, n = 4 per group, Figure 6b). In addi-
tion, we also confirmed the qPCR results with western blot to detect 
MMP14 expression after GFRα blockade. In accordance with the 
qPCR data, GFRα inhibition suppressed microglial MMP14 upregula-
tion indicating that GDNF signaling in microglia is mediated by GFRα1 
(Figure 6c). Furthermore, we measured whether GFRα1 blockade af-
fects tumor growth in the OBS model and indeed, GFRα1 blockade 
inhibited tumor growth (one-way ANOVA with Tukey's post hoc test, 
F(4, 85) = 8.724, p < 0.0001; specifically, Isotype vs. aGFR, 11.3 ± 0.4 
vs. 8.9 ± 0.4 × 106 μm3, p = 0.0338, n = 18 per group, Figure 6d). We 
also tested whether the enhanced tumor growth induced by exog-
enous GDNF could be abrogated by GFRα1 blockade. While GDNF 
increased tumor volume as compared to control (one-way ANOVA 
with Tukey's post hoc test, F(4, 85) = 8.724, p < 0.0001; specifi-
cally, Isotype vs. GDNF+Isotype, 13.7 ± 0.7 vs. 11.3 ± 0.4 × 106μm3, 
p = 0.0341, n = 18 per group, Figure 6d), the antibody against GFRα1 
abolished the effect of GDNF (one-way ANOVA with Tukey's post 
hoc test, F(4, 85) = 8.724, p < 0.0001; specifically, GDNF+Isotype 
vs. GDNF+aGFR1, 13.7 ± 0.7 vs. 10.9 ± 0.5 × 106 μm3, p = 0.007, 
n = 18 per group, Figure 6d). We again confirm this tumor volume 
effect by analyzing the expansion area and we found that GFRα1 
attenuated the effect of GDNF (Figure 6e). To exclude a toxic ef-
fect of GFR blockade on organotypic brain slices, we examined the 
viability of the slices after GFR blockade by the CCK-8 cell viability 
kit. There is no difference in viability after GFR blockade (Figure 6e). 
Furthermore, using clodronate liposome to deplete microglia from 
the slices, we also determined that MMP14 attenuation by GFR 
blockade (Figure 6f) and tumor suppression depends on the pres-
ence of microglia (one-way ANOVA with Tukey's post hoc test, F(3, 
68) = 10.81, p < 0.0001; specifically, aGFR vs. clodronate + aGFR, 
p = 0.0640, n = 18 per group, Figure 6g).
4  | DISCUSSION
Glioblastoma is infiltrated by microglia and peripheral monocytes 
which can account for 30% of the tumor mass. These GAMs have 
been recognized as tumor-promoting elements and a variety of 
mechanisms have been identified how GAMs interact with glioma 
cells (Hambardzumyan et al., 2015). Our group previously identified 
versican as a signaling substance released from glioma cells which 
acts as an endogenous ligand for TLR2 (Hu et al., 2015). Activation of 
TLR2 on GAMs subsequently induces the expression of MMP9 and 
MMP14 which in turn enhance extracellular matrix remodeling and 
subsequently promotes glioma expansion (Vinnakota et al., 2013). 
Here we identified a second signaling pathway which in concert with 
TLR2 signaling also results in the promotion of MMP9 and MMP14 
expression, namely the GDNF/GFRα1 signaling pathway.
F I G U R E  5   Glial cell line-derived neurotrophic factor (GDNF) promotes tumor growth in organotypic brain slice cultures. (a) Scheme of 
the experimental arrangement. Brain slices were obtained from mouse cortex. Tumor cells were inoculated at day 1, and treatment including 
GDNF, isotype or anti-GFR antibody was added into the culture medium at day 2. (b) Representative figures of fluorescently labeled glioma 
GL261 glioma cells after confocal z-stack analysis and 3D reconstruction by IMARIS under control conditions and after treatment with 
1,000, 2,000, 4,000 ng/ml GDNF. (c) Quantification of tumor volume and area after treatment with 1,000, 2,000, and 4,000 ng/ml GDNF. 
(d) Quantification of tumor volume after microglia depletion with clodronate liposomes and subsequent treatment with 4,000 ng/ml GDNF 
(n = 18 each group). (e) Tumor volume after treatment with GDNF neutralizing antibody (aGDNF) and isotype control antibody (n = 18 each 
group). (f) Protein was isolated from organotypic brain slice (OBS) tissue and MMP14 expression was determined by western blot with and 
without GL261 inoculation and with and without treatment with GDNF. The lane on the right shows the protein expression from cultured 
GL261. The sample blot is shown on the left, the quantification on the right (n = 4 each group). (g) Cell proliferation of GL261 cells in vitro 
treated with 1,000, 2,000, 4,000 ng/ml was measured by the CCK-8 kit and normalized to control without GDNF (n = 3 each group). Tumor 
volume data represent three independent experiments, and tumor volume and area was quantified (n = 12 tumors for control and 1,000 ng/
ml group, n = 16 tumors for 2,000 and 4,000 ng/ml group). (h) OBS were pretreated with clodronate to deplete microglia and exposed to 
4,000 ng/ml GDNF. Protein was isolated from OBS tissue and MMP14 expression was determined by western blot. (i) The supernatant of 
cultured slices in (h) was measured to evaluate MMP14 levels via ELISA assay. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, and ns, no 
significance [Color figure can be viewed at wileyonlinelibrary.com]
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In the normal brain, GDNF is expressed by astrocytes and neu-
rons while in a glioma context GDNF is also strongly expressed in the 
glioma cells (Duarte Azevedo et al., 2020; Wiesenhofer et al., 2000). 
The strong GDNF expression in the high-grade glioma is due to si-
lencer II hypermethylation and hyperacetylation of histone H3K9 at 
Egr-1 binding sites in the gdnf promoter II, which further regulate 
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the binding capability of several transcription factors and RNA 
polymerase II (Yu et al., 2013; Zhang et al., 2014, 2016). In a pre-
vious study, we have already described that GDNF facilitated the 
infiltration of microglia into the tumor zone via GFRα signaling (Ku 
et al., 2013). In that study we also demonstrated that injection of 
GL261 mouse glioma cells with GDNF knockdown into mouse 
brains resulted in reduced tumor expansion and improved survival 
as compared to injection of control cells (Ku et al., 2013). Using the 
TCGA database we found a correlation between GDNF and MMP14 
expression and therefore addressed the question whether GDNF 
signaling might trigger MMP expression. By stimulating primary 
microglia with murine recombinant GDNF, we indeed observed an 
upregulation of microglial MMP9 and MMP14 mRNA and protein 
expression. GDNF was mediated by GFRα receptor signaling, since 
we could block the upregulation of GDNF-induced MMP14 upreg-
ulation by a GFRα blocking antibody. The GFRα1 signaling pathway 
could also be exploited by other ligands since neural cell adhesion 
molecule can mediate GFRα signaling (Charoy et al., 2012; Duveau & 
Fritschy, 2010; Euteneuer et al., 2013; Nielsen et al., 2009).
We have previously shown that the TLR2-induced upregulation 
of MMP14 is mediated by p38 MAPK signaling (Hu et al., 2015; 
Vinnakota et al., 2013). Here we now found that GDNF-mediated 
GFRα receptor signaling converges on the same pathway. We found 
that GDNF-induced p38 MAPK/p-Mk2 activation and that blockade 
of p38 MAPK impaired the GDNF-induced upregulation of MMP14. 
Moreover, we found that GDNF also affects the TLR2 signaling path-
way. Our findings indicate that GDNF upregulated TLR1 and 2 but 
not TLR6 expression on microglia in a p38/mk2-dependent manner, 
indicating that GDNF signaling results in a higher level of TLR2 expres-
sion. The upregulation of TLR2 could further amplify the MMP9 and 
MMP14 expression since the TLR2 is crucial receptor for controlling 
the MMP9 and 14 expression (Hu et al., 2014; Vinnakota et al., 2013).
MMP9 and MMP14 facilitate the degradation of the extracellular 
matrix which facilitate glioma cell invasion. Here, indeed, GDNF did 
promote glioma growth and this promoting effect was based on the 
presence of microglia indicating that microglia promote the GDNF-
mediated glioma growth. We also could confirm that GFRα signaling 
mediates the GDNF-induced glioma growth since the GFRα blocking 
antibody interfered with the GDNF promoting glioma growth. And 
however, this study only includes organotypic brain slices, which re-
quire in vivo experiment to test potential usage for glioma treatment. 
In conclusion, we demonstrated that GDNF released from glioma 
could induce increased expression of MMP9/14 in microglia in 
GFRα/p38/mk2-dependent manner, which facilitates glioma growth.
5  | CONCLUSIONS
We here demonstrate that GDNF activates GFRa1 on microglia to 
induce MMP9 and MMP14 upregulation via p38 MAPK signaling, 
which promote glioma growth on the ex vivo level. Based on our 
previous work, these findings illustrate that GDNF promotes glioma 
progression and this pathway represents a potential therapy target.
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isotype antibody served as control (n = 4 each group). (c) Protein level of MMP14 expression was measured by western blot after treatment 
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with and without 4,000 ng/ml GDNF. Isotype served as a control. Tumor volume (left) and area (right) were measured. Tumor volume data 
represent four independent experiments, and tumor volume and area was quantified from 18 tumors. (e) Viability of organotypic brain slices 
(OBS) treated with 1 µg/ml aGFR were determined by CCK-8 kit. (f) OBS were treated with liposome for microglia depletion prior to tumor 
inoculation and 1 µg/ml aGFR was applied. MMP14 expression level of the OBS tissue was measured by western blot. (g) OBS were treated 
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FIGURE S1. (a) qPCR results of MMP9 and MMP14 expression 
after microglia treated with 0.1% BSA buffer. (b) qPCR results of 
MMP9 and MMP14 expression after microglia treated with 1,000 
or 4,000 ng/ml GDNF (dissolved in PBS) for 6 hr. (c, d) Microglial 
TLR1 and TLR2 mRNA level change after treated with 1,000 or 
4,000 ng/ml GDNF (dissolved in PBS). (e and f) Correlation data 
of MMP9 with AIF1 or MMP14 with AIF1 were performed by 
using GLIOVIS website (http://gliov is.bioin fo.cnio.es/) acquired 
from GBM TCGA database. *p < 0.05, **p < 0.01,***p < 0.001, and 
****p < 0.0001
FIGURE S2. (a) Representative figures of organotypic brain slices 
(Macgreen mice) with GL261mCherry (red) tumor inoculation with 
our without microglia (green). Scale bar = 100 µm. (b) Representative 
figures of microglia (Ionized calcium binding adaptor molecule 1, Iba-
1, green), neurons (NeuN, gray) and astrocytes (Glial fibrillary acidic 
protein, GFAP, red) in organotypic brain slices (BL6 mice) with or 
without microglia (green). Scale bar = 200 µm
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